Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. BJS 2017; 104: 1568-1577.
Published: 22nd August 2017
Authors: L. G. M. van der Geest, V. E. P. P. Lemmens, I. H. J. T. de Hingh, C. J. H. M. van Laarhoven, T. L. Bollen, C. Y. Nio et al.
Despite improvements in diagnostic imaging and staging, unresectable pancreatic cancer is still encountered during surgical exploration with curative intent. This nationwide study investigated outcomes in patients with unresectable pancreatic cancer found during surgical exploration.
All patients diagnosed with primary pancreatic (adeno)carcinoma (2009–2013) in the Netherlands Cancer Registry were included. Predictors of unresectability, 30‐day mortality and poor survival were evaluated using logistic and Cox proportional hazards regression analysis.
There were 10 595 patients with pancreatic cancer during the study interval. The proportion of patients undergoing surgical exploration increased from 19·9 to 27·0 per cent (
Exploration and resection rates increased, but one‐third of patients who had surgical exploration for pancreatic cancer did not undergo resection. Non‐resectional surgery doubled the 30‐day mortality rate compared with that in patients undergoing tumour resection.Read more
You may also be interested in
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Randomized clinical trial
Randomized clinical trial of duct‐to‐mucosa versus invagination pancreaticojejunostomy after pancreatoduodenectomy. BJS 2018; 105: 48-57.
Authors: Y. Senda, Y. Shimizu, S. Natsume, S. Ito, K. Komori, T. Abe et al.
Notes: No difference found
Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent.
Authors: X.‐F. Zhang, E. W. Beal, F. Bagante, J. Chakedis, M. Weiss, I. Popescu et al.
Notes: Early recurrence is bad news
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth